Latest Updates

Previously served on USP’s Board of Trustees

P7435 is a novel DGAT1 inhibitor for treatment of lipid disorders and diabetes

Gets certification for Good Laboratory Practices norms on OECD Principles by the National GLP and Compliance Monitoring Authority

The campaign puts the spotlight on heart disease in women

EBITDA margins reported at 17.5 per cent

Approval under the PEPFAR scheme, total PEPFAR approvals at 20

Ranexa tablets, 500 mg and 1000 mg had US sales of approximately $ 443.4 million

Consolidated Net Profit increased by 64.38 per cent to Rs. 1286.76 million in Q1 FY13-14

PIL petitioners to submit suggestions in two weeks; ISCR expresses concerns on slowdown of trial approvals

Capitol Ingredients will be consolidated with staff from the IMCD Personal Care team and will run as a separate division of IMCD…